Health Condition 1: M959- Acquired deformity of musculoskeletal system, unspecified
Conditions
Interventions
None listed
Sponsors
State Ayurvedic College and Hospital Lucknow
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age: Individuals between 21 and 60 years. 2. Gender: Both males and females will be included. 3. Socioeconomic Status: Participants from all socioeconomic backgrounds are eligible. 4. In case of Jalauka Avcharana BT, CT, INR, within normal limits and patients having HB percent grater than 10 gm percent. 5. Clinical Parameters: Patients diagnosed with Vatarakt who have serum uric acid levels exceeding 7 mg per dl in males and 6 mg per dl in females. Additionally, they must fulfill all three essential diagnostic criteria along with at least one non-essential criterion.
Exclusion criteria
Exclusion criteria: 1. Individuals younger than 21 years or older than 60 years. 2. In case of Jalauka Avcharana patient having HB percentage less than 10gm percentage, any coagulative disorders, uncontrolled hypertension and Diabetes mellitus. 3. Cases of gouty arthritis complicated by systemic conditions such as uncontrolled diabetes, thyroid dysfunctions, or psoriatic arthritis. 4. Patients with advanced Vatarakta presenting with complications like hiccups, fainting, delirium, erysipelas, muscular abscess, or finger deformities. 5. Gout cases accompanied by chronic joint deformity, significant loss of joint function, or presence of draining tophi. 6. Women who are pregnant or Lactating., 7. Patients diagnosed with rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus ,tuberculosis, or those suffering from renal or liver disorders. 8. Patients having serum uric acid grater than 10.3 mg per dl in females and grater than 11.6 mg per dl in males.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To establish the comparative efficacy of Punarnava amrita guggulu & Rasnadi kwath in case of Vatrakta with and without raktmokshan (by Jaluka). 2.To evaluate the clinical efficacy of Punarnava Amrita Guggulu and Rasnadi Kwath in the management of Vatarakta (Gout), with and without Raktamokshana (Jaluka).Timepoint: Duration of clinical trial - 30 days. Follow up during treatment 7, 15, 30 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess the role of Raktamokshana (Jaluka) as an adjunct to oral therapy in reducing symptoms such as Shotha (swelling), Shula (pain), and Daha (burning) in Vatarakta. 2. To compare the therapeutic outcomes between the two groups: o Group A: Treated with Punarnava Amrita Guggulu and Rasnadi Kwath alone. o Group B: Treated with Punarnava Amrita Guggulu, Rasnadi Kwath, and Raktamokshana. 3. To analyze improvements in subjective parameters weekly and objective parameter like serum uric acid level at 0, 15th and 30th day of trial. 4. To assess the side effect of drugs and Raktmoksan (by jaluka) if any.Timepoint: 1.Duration of clinical trial - 30 days. 2.Follow up during treatment 7, 15, 30 days 3.Follow up without drug 7 days. (Jaluka Avshechan Once in a week for 1 month at morning i.e. total 5 times during complete trial at the day 0, 7, 14, 21, 28 days.) | — |
Countries
India
Contacts
Public ContactDr Sharad Johri
State Ayurvedic College and Hospital Lucknow
Outcome results
None listed